Outcome: ever diagnosis | ||||||
---|---|---|---|---|---|---|
Outcome | OR (CI) | |||||
1. Quartile | 2. Quartile | 3. Quartile | 4. Quartile | Continuous [per 10 nmol/l] | ||
Asthma male | Cases/Non-diseased (% Cases) | 34/265 (11%) | 35/297 (11%) | 25/282 (8%) | 39/303 (11%) | 133/1147 (10%) |
Adjusted model1 | 1 | 0.84 (0.50;1.40) | 0.65 (0.37;1.13) | 0.97 (0.59;1.61) | 1.00 (0.92;1.07) | |
Asthma female | Cases/Non-diseased (% Cases) | 15/295 (5%) | 22/281 (7%) | 22/289 (7%) | 17/278 (6%) | 76/1143 (6%) |
Adjusted model1 | 1 | 1.54 (0.78;3.06) | 1.48 (0.74;2.93) | 1.21 (0.59;2.50) | 1.02 (0.92;1.13) | |
Eczema | Cases/Non-diseased (% Cases) | 173/430 (29%) | 196/430 (31%) | 184/420 (30%) | 195/433 (31%) | 748/1713 (30%) |
Adjusted model2 | 1 | 1.12 (0.87;1.44) | 1.09 (0.84;1.40) | 1.14 (0.89;1.46) | 1.05* (1.01;1.09) | |
Hay fever or allergic rhinitis | Cases/Non-diseased (% Cases) | 99/504 (16%) | 119/507 (19%) | 117/487 (19%) | 121/507 (19%) | 456/2005 (19%) |
Adjusted model2 | 1 | 1.13 (0.84;1.53) | 1.16 (0.86;1.57) | 1.15 (0.85;1.56) | 1.02 (0.98;1.07) |